The company manufactures and markets finished dosage formulations in 50+ countries, including the US, Canada, Brazil, and Europe, with international business focused on Para IV and first-to-file molecules and plans to expand into emerging markets like MENA, LATAM, and Southeast Asia. Management is strategically prioritizing mergers and acquisitions to achieve a long-term turnover goal of INR 10,000 crores, with upcoming product launches particularly in oncology and generics like semaglutide expected to enhance revenue.
Cyborg Score Rationale
Net profit rose 13.91% to Rs 151.50 crore in Q3 FY26 and sales rose 36.33% to Rs 647.30 crore in the same quarter. The company demonstrates solid fundamentals with strategic expansion plans, though recent revenue volatility and regulatory challenges present headwinds.
Top Insights
Natco Pharma received CDSCO approval for Semaglutide to manufacture and market generic Semaglutide Injection in India with planned launch in March 2026.
The company obtained compulsory license to produce a cheaper generic version of Bayer's anti-cancer medication Nexavar in 2012, a landmark achievement in affordable oncology medicines.
Major US partners include Sun-Ranbaxy, Aceto-Rising, Alvogen, Teva, Mylan, Actavis, and Lupin.
The P/E ratio of Natco Pharma is 9.39, indicating attractive valuation relative to earnings.
Named Competitors
Oncology & Generic Medicines — Indian pharmaceutical company competing in generics and specialty medicines
APIs & Formulations — Active pharmaceutical ingredients and formulations manufacturer
Generics & Specialty — Global pharmaceutical company focused on generics and specialty medicines
Recent Developments
(Feb 2026) CDSCO Semaglutide approval confirmed with launch planned for March 2026 under Eris partnership.
(Dec 2025) Q3 FY26 net profit rose 13.91% to Rs 151.50 crore and sales rose 36.33% to Rs 647.30 crore.
(Feb 2026) Board recommended interim dividend of Rs 1.5 per equity share (75%), subject to shareholder approval.
Open the full interactive Natco Pharma Limited report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.